메뉴 건너뛰기




Volumn 23, Issue 3, 2017, Pages 267-275

Real-world glycemic control from GLP-1RA therapy with and without concurrent insulin in patients with type 2 diabetes

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; EXENDIN 4; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN; PEPTIDE; VENOM;

EID: 85013928085     PISSN: 23760540     EISSN: 23761032     Source Type: Journal    
DOI: 10.18553/jmcp.2017.16334     Document Type: Article
Times cited : (10)

References (16)
  • 1
    • 84975856269 scopus 로고    scopus 로고
    • Economic costs of diabetes in the U.S
    • American Diabetes Association. Economic costs of diabetes in the U.S. in 2012 Diabetes Care. 2013;36(4):1033-46.
    • (2013) in 2012 Diabetes Care , vol.36 , Issue.4 , pp. 1033-1046
  • 2
    • 84855690825 scopus 로고    scopus 로고
    • Effective interventions for stemming the growing crisis of diabetes and prediabetes: a national payer's perspective
    • Vojta D, De Sa J, Prospect T, Stevens S. Effective interventions for stemming the growing crisis of diabetes and prediabetes: a national payer's perspective. Health Aff(Millwood). 2012;31(1):20-26.
    • (2012) Health Aff(Millwood) , vol.31 , Issue.1 , pp. 20-26
    • Vojta, D.1    De Sa, J.2    Prospect, T.3    Stevens, S.4
  • 3
    • 84960878943 scopus 로고    scopus 로고
    • 2016 standards of medical care in diabetes
    • American Diabetes Association. 2016 standards of medical care in diabetes. Diabetes Care. 2016;39(Supplement 1):S1-2.
    • (2016) Diabetes Care , vol.39 , pp. S1-S2
  • 4
    • 84856075028 scopus 로고    scopus 로고
    • Comprehensive diabetes care. October 1. Accessed January 25, 2017
    • National Committee for Quality Assurance. HEDIS 2009 Volume 2 technical update. Comprehensive diabetes care. October 1, 2008. Available at: http://www.ncqa.org/portals/0/PolicyUpdates/HEDIS%20Technical%20 Updates/09_CDC_Spec.pdf. Accessed January 25, 2017.
    • (2008) HEDIS 2009 Volume 2 technical update
  • 6
    • 85021361996 scopus 로고    scopus 로고
    • Accessed January 16, 2017
    • Centers for Medicare & Medicaid Services. Quality payment program. 2016 Available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Value-Based-Programs/MACRA-MIPSand-APMs/Quality-Payment-Program-MACRA-NPRM-Slides.pdf. Accessed January 16, 2017.
    • (2016) Quality payment program
  • 7
    • 84982995031 scopus 로고    scopus 로고
    • AACE/ACE comprehensive diabetes management algorithm, 2015
    • Garber AJ, Abrahamson MJ, Barzilay Jl, et al. AACE/ACE comprehensive diabetes management algorithm, 2015. Endocr Pract. 2015;21(4):438-47.
    • (2015) Endocr Pract , vol.21 , Issue.4 , pp. 438-447
    • Garber, A.J.1    Abrahamson, M.J.2    Barzilay, J.3
  • 8
    • 84872084453 scopus 로고    scopus 로고
    • Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
    • Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117-24.
    • (2013) Lancet , vol.381 , Issue.9861 , pp. 117-124
    • Buse, J.B.1    Nauck, M.2    Forst, T.3
  • 9
    • 84924289309 scopus 로고    scopus 로고
    • Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes
    • Blonde L, Pencek R, MacConell L. Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:12.
    • (2015) Cardiovasc Diabetol , vol.14 , pp. 12
    • Blonde, L.1    Pencek, R.2    MacConell, L.3
  • 10
    • 84922790807 scopus 로고    scopus 로고
    • GLP-1 receptor agonists: a review of head-to-head clinical studies
    • Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2015;6(1):19-28.
    • (2015) Ther Adv Endocrinol Metab , vol.6 , Issue.1 , pp. 19-28
    • Trujillo, J.M.1    Nuffer, W.2    Ellis, S.L.3
  • 13
    • 84942578393 scopus 로고    scopus 로고
    • Why summary comorbidity measures such as the Charlson Comorbidity Index and Elixhauser Score work
    • Austin SR, Wong YN, Uzzo RG, Beck JR, Egleston BL. Why summary comorbidity measures such as the Charlson Comorbidity Index and Elixhauser Score work. Med Care. 2015;53(9):e65-72.
    • (2015) Med Care , vol.53 , Issue.9 , pp. e65-e72
    • Austin, S.R.1    Wong, Y.N.2    Uzzo, R.G.3    Beck, J.R.4    Egleston, B.L.5
  • 14
    • 84920855422 scopus 로고    scopus 로고
    • Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis
    • Sun F, Wu S, Wang J, et al. Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. Clin Ther. 2015;37(1):225-41.
    • (2015) Clin Ther , vol.37 , Issue.1 , pp. 225-241
    • Sun, F.1    Wu, S.2    Wang, J.3
  • 15
    • 84879800350 scopus 로고    scopus 로고
    • Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials
    • Wang B, Zhong J, Lin H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab. 2013;15(8):737-49.
    • (2013) Diabetes Obes Metab , vol.15 , Issue.8 , pp. 737-749
    • Wang, B.1    Zhong, J.2    Lin, H.3
  • 16
    • 84860638209 scopus 로고    scopus 로고
    • The cardiovascular effects of GLP-1 receptor agonists
    • Okerson T, Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther. 2012;30(3):e146-55.
    • (2012) Cardiovasc Ther , vol.30 , Issue.3 , pp. e146-e155
    • Okerson, T.1    Chilton, R.J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.